The LVAD results were quite encouraging for CHF trial if you looked at it carefully, but I do think CHF is the most high risk of all the MSB trials.
Rather than a total failure (unlikely after the interim results), the biggest risk is that the benefit is minor and below the threshold at which insurance companies will pay for the treatment. It is important to keep in mind that MSB doesn't fail as a company if the CHF trial fails - there is plenty of upside at the current SP just in what we know works.
- Forums
- ASX - By Stock
- MSB
- Ann: P3 Trial of MSB's Cell Therapy in CHF Completes Recruitment
Ann: P3 Trial of MSB's Cell Therapy in CHF Completes Recruitment, page-29
-
- There are more pages in this discussion • 24 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add MSB (ASX) to my watchlist
(20min delay)
|
|||||
Last
$1.32 |
Change
-0.005(0.38%) |
Mkt cap ! $1.478B |
Open | High | Low | Value | Volume |
$1.31 | $1.32 | $1.28 | $977.1K | 754.2K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
15 | 7978 | $1.31 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.32 | 15147 | 5 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
5 | 262 | 1.310 |
8 | 7479 | 1.305 |
11 | 60808 | 1.300 |
12 | 134003 | 1.295 |
11 | 44858 | 1.290 |
Price($) | Vol. | No. |
---|---|---|
1.315 | 17594 | 5 |
1.320 | 13363 | 5 |
1.325 | 4999 | 2 |
1.330 | 21513 | 5 |
1.335 | 18770 | 2 |
Last trade - 12.29pm 01/11/2024 (20 minute delay) ? |
Featured News
MSB (ASX) Chart |